Steve Wooding is the Head, Global Commercial Strategy and Market Access Organisation, a position he assumed in June 2015. He is a member of the Pharmaceuticals Group Operating Committee (GOC) reporting to Joaquin Duato.
In this role, Steve leads the Global Commercial Strategy Organisation (GCSO), with primary responsibility for the ongoing evolution and stewardship of Janssen 2020, our shared vision and global strategy to drive transformational medical innovation and position Janssen as a global pharmaceuticals leader. Steve and his team help identify and adapt to market challenges, develop new strategies for growth and in partnership with our research and development colleagues, seize opportunities to continue to transform the lives of patients around the world. Steve also has responsibility for Janssen Healthcare Innovation.
Most recently, Steve was Managing Director, Emerging Markets, Janssen EMEA, with commercial responsibility for Central and Eastern Europe (CEE), Middle East, North and West Africa, Turkey, South Africa and Sub-Saharan Africa. Before this as Vice President and Head of Market Access for EMEA, he built an integrated Market Access function, bringing together teams from the Commercial Strategy, Medical Affairs, Health Economics and Market Access, New Business Development, Business Intelligence organisations to provide rapid and sustained patient access to our innovative new drugs. Prior to this, Steve was Vice President, Medical Affairs, Janssen EMEA. His strong vision for the future helped focus all Medical Affairs activities in Janssen EMEA and create a more cohesive and aligned function.
Previously, Steve served as Area Managing Director for Janssen UK, Ireland and South Africa, and Managing Director for Australia and New Zealand. He joined Johnson & Johnson with Janssen UK in 1992, and held several positions of increasing responsibility within R&D, Medical Affairs and Commercial in the UK, Ireland, South Africa and Canada.
Steve earned a BSc degree in Pharmacology and MB, BS from St. Bartholomew’s Hospital in London; he is a Fellow of the Faculty of Pharmaceutical Medicine and holds an MBA from Henley Management College, UK.